Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prost...(data than expected the risk that the FDA...),Health

Date:10/23/2007

data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

'/>"/>

SOURCE Dendreon Corporation Copyright©2007 PR Newswire. All rights reserved

7 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
7. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
10. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
11. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers